← All trials
NCT06278389
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 24, 2024
- Primary completion
- Apr 23, 2024
- Completion date
- Apr 23, 2024
- First posted
- Feb 26, 2024
- Last posted
- Mar 5, 2024
- Enrollment
- 52
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiangsu Aidea Pharmaceutical Co., LtdLead sponsor
- Jiangsu Aidea Pharmaceutical Co., LtdCollaborator
- Capital Medical UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.